{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:05:16Z","timestamp":1791266716673,"version":"4.1.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s12035-008-8019-y","type":"journal-article","created":{"date-parts":[[2008,8,8]],"date-time":"2008-08-08T14:20:23Z","timestamp":1218205223000},"page":"1-15","source":"Crossref","is-referenced-by-count":84,"title":["The ART of Loss: A\u03b2 Imaging in the Evaluation of Alzheimer\u2019s Disease and other Dementias"],"prefix":"10.1007","volume":"38","author":[{"given":"Victor L.","family":"Villemagne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle T.","family":"Fodero-Tavoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryn E.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cappai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,9]]},"reference":[{"key":"8019_CR1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1471-4159.2006.03989.x","volume":"97","author":"CL Masters","year":"2006","unstructured":"Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for Alzheimer\u2019s disease: implications for neuroimaging and therapeutics. J Neurochem 97:1700\u20131725","journal-title":"J Neurochem"},{"key":"8019_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0011-5029(00)90028-2","volume":"46","author":"DA Bennett","year":"2000","unstructured":"Bennett DA (2000) Part I. Epidemiology and public health impact of Alzheimer\u2019s disease. Dis Mon 46:657\u2013665","journal-title":"Dis Mon"},{"key":"8019_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00019053-200018030-00002","volume":"18","author":"N Johnson","year":"2000","unstructured":"Johnson N, Davis T, Bosanquet N (2000) The epidemic of Alzheimer\u2019s disease. How can we manage the costs. Pharmacoeconomics 18:215\u2013223","journal-title":"Pharmacoeconomics"},{"key":"8019_CR4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/(SICI)1099-1166(199908)14:8<651::AID-GPS992>3.0.CO;2-B","volume":"14","author":"J Schneider","year":"1999","unstructured":"Schneider J, Murray J, Banerjee S, Mann A (1999) EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer\u2019s disease: I\u2014Factors associated with carer burden. Int J Geriatr Psychiatry 14:651\u2013661","journal-title":"Int J Geriatr Psychiatry"},{"key":"8019_CR5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298:789\u2013791","journal-title":"Science"},{"key":"8019_CR6","first-page":"393","volume-title":"Dementia","author":"CL Masters","year":"2005","unstructured":"Masters CL (2005) Neuropathology of Alzheimer\u2019s disease. In: Burns A, O\u2019Brien J, Ames D (eds) Dementia. 3rd edn. Hodder Arnold, London, pp 393\u2013407","edition":"3"},{"key":"8019_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/CBO9780511544873.030","volume-title":"Neurodegenerative diseases: neurobiology, pathogenesis and therapeutics","author":"CL Masters","year":"2005","unstructured":"Masters CL, Beyreuther K (2005) The neuropathology of Alzheimer\u2019s disease in the year 2005. In: Beal MF, Lang AE, Ludolph AC (eds) Neurodegenerative diseases: neurobiology, pathogenesis and therapeutics. Cambridge University Press, Cambridge, pp 433\u2013440"},{"key":"8019_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-7091-3396-5_6","volume-title":"Alzheimer disease: epidemiology, neuropathology, neurochemistry, and clinics","author":"K Jellinger","year":"1990","unstructured":"Jellinger K (1990) Morphology of Alzheimer disease and related disorders. In: Maurer K, Riederer P, Beckmann H (eds) Alzheimer disease: epidemiology, neuropathology, neurochemistry, and clinics. Springer, Berlin, pp 61\u201377"},{"key":"8019_CR9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1385\/JMN:19:3:289","volume":"19","author":"ML Michaelis","year":"2002","unstructured":"Michaelis ML, Dobrowsky RT, Li G (2002) Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 19:289\u2013293","journal-title":"J Mol Neurosci"},{"key":"8019_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-7091-7508-8_8","volume":"54","author":"KA Jellinger","year":"1998","unstructured":"Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer\u2019s disease: a critical update. J Neural Transm Suppl 54:77\u201395","journal-title":"J Neural Transm Suppl"},{"key":"8019_CR11","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245\u20134249","journal-title":"Proc Natl Acad Sci USA"},{"key":"8019_CR12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1357-2725(99)00027-8","volume":"31","author":"R Cappai","year":"1999","unstructured":"Cappai R, White AR (1999) Amyloid beta. Int J Biochem Cell Biol 31:885\u2013889","journal-title":"Int J Biochem Cell Biol"},{"key":"8019_CR13","first-page":"5","volume-title":"The abeta centric pathway of Alzheimer\u2019s disease, in abeta peptide and Alzheimer\u2019s disease","author":"VL Villemagne","year":"2006","unstructured":"Villemagne VL, Cappai R, Barnham KJ, Cherny R, Opazo C, Novakovic KE, Rowe CC, Masters CL (2006) In: Barrow CJ, Small BJ (eds) The abeta centric pathway of Alzheimer\u2019s disease, in abeta peptide and Alzheimer\u2019s disease. Springer, London, pp 5\u201332"},{"key":"8019_CR14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ (1991) The molecular pathology of Alzheimer\u2019s disease. Neuron 6:487\u2013498","journal-title":"Neuron"},{"key":"8019_CR15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"8019_CR16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0166-2236(02)02263-4","volume":"25","author":"F Checler","year":"2002","unstructured":"Checler F, Vincent B (2002) Alzheimer\u2019s and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci 25:616\u2013620","journal-title":"Trends Neurosci"},{"key":"8019_CR17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1126\/science.298.5595.962","volume":"298","author":"SR Robinson","year":"2002","unstructured":"Robinson SR, Bishop GM (2002) The search for an amyloid solution. Science 298:962\u2013964 author reply 962\u2013964","journal-title":"Science"},{"key":"8019_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0166-2236(96)01030-2","volume":"20","author":"J Hardy","year":"1997","unstructured":"Hardy J (1997) Amyloid, the presenilins and Alzheimer\u2019s disease. Trends Neurosci 20:154\u2013159","journal-title":"Trends Neurosci"},{"key":"8019_CR19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Ab amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol 46:860\u2013866","journal-title":"Ann Neurol"},{"key":"8019_CR20","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1097\/00001756-199909290-00007","volume":"10","author":"MS Mega","year":"1999","unstructured":"Mega MS, Chu T, Mazziotta JC, Trivedi KH, Thompson PM, Shah A, Cole G, Frautschy SA, Toga AW (1999) Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer\u2019s disease. Neuroreport 10:2911\u20132917","journal-title":"Neuroreport"},{"key":"8019_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.410380219","volume":"38","author":"SM Greenberg","year":"1995","unstructured":"Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38:254\u2013259","journal-title":"Ann Neurol"},{"key":"8019_CR22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3233\/JAD-2001-3305","volume":"3","author":"CA McLean","year":"2001","unstructured":"McLean CA, Beyreuther K, Masters CL (2001) Amyloid abeta levels in Alzheimer\u2019s disease\u2014a diagnostic tool and the key to understanding the natural history of abeta. J Alzheimers Dis 3:305\u2013312","journal-title":"J Alzheimers Dis"},{"key":"8019_CR23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","volume":"283","author":"J Naslund","year":"2000","unstructured":"Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama 283:1571\u20131577","journal-title":"Jama"},{"key":"8019_CR24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol 155:853\u2013862","journal-title":"Am J Pathol"},{"key":"8019_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/exnr.1999.7085","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Ab distinguish Alzheimer\u2019s disease from normal and pathologic aging. Exp Neurol 158:328\u2013337","journal-title":"Exp Neurol"},{"key":"8019_CR26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535\u2013539","journal-title":"Nature"},{"key":"8019_CR27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1042\/BST0331087","volume":"33","author":"DM Walsh","year":"2005","unstructured":"Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ (2005) The role of cell-derived oligomers of abeta in Alzheimer\u2019s disease and avenues for therapeutic intervention. Biochem Soc Trans 33:1087\u20131090","journal-title":"Biochem Soc Trans"},{"key":"8019_CR28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"8019_CR29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1212\/WNL.56.9.1133","volume":"56","author":"RC Petersen","year":"2001","unstructured":"Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review)\u2014report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1133\u20131142","journal-title":"Neurology"},{"key":"8019_CR30","first-page":"93","volume":"15","author":"RC Petersen","year":"2000","unstructured":"Petersen RC (2000) Mild cognitive impairment: transition between aging and Alzheimer\u2019s disease. Neurologia 15:93\u2013101","journal-title":"Neurologia"},{"key":"8019_CR31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303\u2013308","journal-title":"Arch Neurol"},{"key":"8019_CR32","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/brain\/awl251","volume":"129","author":"CL Masters","year":"2006","unstructured":"Masters CL, Beyreuther K (2006) Alzheimer\u2019s centennial legacy: prospects for rational therapeutic intervention targeting the abeta amyloid pathway. Brain 129:2823\u20132839","journal-title":"Brain"},{"key":"8019_CR33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/197140090601900406","volume":"19","author":"VL Villemagne","year":"2006","unstructured":"Villemagne VL, Ng S, Cappai R, Barnham KJ, Fodero-Tavoletti MT, Rowe CC, Masters CL (2006) La Lunga Attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer\u2019s disease. The Neuroradiology Journal 19:51\u201375","journal-title":"The Neuroradiology Journal"},{"key":"8019_CR34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0140-6736(92)92890-R","volume":"340","author":"KA Jobst","year":"1992","unstructured":"Jobst KA, Smith AD, Szatmari M, Molyneux A, Esirs ME, King E, Smith A, Jaskowski A, McDonald B, Wald N (1992) Detection in life of confirmed Alzheimer\u2019s idsease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340:1179\u20131183","journal-title":"Lancet"},{"key":"8019_CR35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1148\/radiol.2262011600","volume":"226","author":"JR Petrella","year":"2003","unstructured":"Petrella JR, Coleman RE, Doraiswamy PM (2003) Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226:315\u2013336","journal-title":"Radiology"},{"key":"8019_CR36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(02)00035-2","volume":"1","author":"SI Rapoport","year":"2002","unstructured":"Rapoport SI (2002) Hydrogen magnetic resonance spectroscopy in Alzheimer\u2019s disease. Lancet Neurol 1:82","journal-title":"Lancet Neurol"},{"key":"8019_CR37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.58.6.928","volume":"58","author":"N Schuff","year":"2002","unstructured":"Schuff N, Capizzano AA, Du AT, Amend DL, O\u2019Neill J, Norman D, Kramer J, Jagust W, Miller B, Wolkowitz OM, Yaffe K, Weiner MW (2002) Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58:928\u2013935","journal-title":"Neurology"},{"key":"8019_CR38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0197-4580(98)00007-4","volume":"19","author":"K Juottonen","year":"1998","unstructured":"Juottonen K, Laakso MP, Insausti R, Lehtovirta M, Pitkanen A, Patanen K, Soininen H (1998) Volumes of the entorhinal and perirhinal cortices in Alzheimer\u2019s disease. Neurobiol Aging 19:15\u201322","journal-title":"Neurobiol Aging"},{"key":"8019_CR39","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1212\/WNL.54.9.1760","volume":"54","author":"Y Xu","year":"2000","unstructured":"Xu Y, Jack CRJ, O\u2019Brien PC, Kokmen E, Smith GE, Ivnik RJ, Boeve BF, Tangalos RG, Petersen RC (2000) Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54:1760\u20131767","journal-title":"Neurology"},{"key":"8019_CR40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1041610297004900","volume":"9","author":"MJ Leon de","year":"1997","unstructured":"de Leon MJ, Convit A, DeSanti S, Bobinski M, George AE, Wisniewski HM, Rusinek H, Carroll R, Saint Louis LA (1997) Contribution of structural neuroimaging to the early diagnosis of Alzheimer\u2019s disease. Int Psychogeriatr 9:183\u2013190 (discussion 247\u2013152)","journal-title":"Int Psychogeriatr"},{"key":"8019_CR41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1749-6632.2000.tb06730.x","volume":"911","author":"L Toledo-Morrell De","year":"2000","unstructured":"De Toledo-Morrell L, Goncharova I, Dickerson B, Wilson RS, Bennett DA (2000) From healthy aging to early Alzheimer\u2019s disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci 911:240\u2013253","journal-title":"Ann N Y Acad Sci"},{"key":"8019_CR42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(05)74869-8","volume":"353","author":"M Bobinski","year":"1999","unstructured":"Bobinski M, de Leon MJ, Convit A, De Santi S, Wegiel J, Tarshish CY, Saint Louis LA, Wisniewski HM (1999) MRI of entorhinal cortex in mild Alzheimer\u2019s disease. Lancet 353:38\u201340","journal-title":"Lancet"},{"key":"8019_CR43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I","volume":"47","author":"RJ Killiany","year":"2000","unstructured":"Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS (2000) Use of structural magnetic resonance imaging to predict who will get Alzheimer\u2019s disease. Ann Neurol 47:430\u2013439","journal-title":"Ann Neurol"},{"key":"8019_CR44","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0197-4580(01)00271-8","volume":"22","author":"BC Dickerson","year":"2001","unstructured":"Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L (2001) MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer\u2019s disease. Neurobiol Aging 22:747\u2013754","journal-title":"Neurobiol Aging"},{"key":"8019_CR45","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/mgme.2001.3236","volume":"74","author":"DH Silverman","year":"2001","unstructured":"Silverman DH, Phelps ME (2001) Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke. Mol Genet Metab 74:128\u2013138","journal-title":"Mol Genet Metab"},{"key":"8019_CR46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jocn.2004.03.011","volume":"12","author":"VL Villemagne","year":"2005","unstructured":"Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL (2005) Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer\u2019s disease. J Clin Neurosci 12:221\u2013230","journal-title":"J Clin Neurosci"},{"key":"8019_CR47","first-page":"661","volume":"41","author":"ME Phelps","year":"2000","unstructured":"Phelps ME (2000) PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41:661\u2013681","journal-title":"J Nucl Med"},{"key":"8019_CR48","first-page":"611","volume":"42","author":"EE Camargo","year":"2001","unstructured":"Camargo EE (2001) Brain SPECT in neurology and psychiatry. J Nucl Med 42:611\u2013623","journal-title":"J Nucl Med"},{"key":"8019_CR49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/snuc.2003.127294","volume":"33","author":"RL Heertum Van","year":"2003","unstructured":"Van Heertum RL, Tikofsky RS (2003) Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 33:77\u201385","journal-title":"Semin Nucl Med"},{"key":"8019_CR50","first-page":"391","volume":"35","author":"E Salmon","year":"1994","unstructured":"Salmon E, Sadzot B, Maquet P, Degueldre C, Lemaire C, Rigo P, Comar D, Franck G (1994) Differential diagnosis of Alzheimer\u2019s disease with PET. J Nucl Med 35:391\u2013398","journal-title":"J Nucl Med"},{"key":"8019_CR51","first-page":"3A","volume":"32","author":"HW Strauss","year":"1991","unstructured":"Strauss HW (1991) The ART of PET. J Nucl Med 32:3A","journal-title":"J Nucl Med"},{"key":"8019_CR52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/archpsyc.1997.01830150083012","volume":"54","author":"DP Devanand","year":"1997","unstructured":"Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y (1997) The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 54:257\u2013263","journal-title":"Arch Gen Psychiatry"},{"key":"8019_CR53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nic.2005.09.007","volume":"15","author":"RE Coleman","year":"2005","unstructured":"Coleman RE (2005) Positron emission tomography diagnosis of Alzheimer\u2019s disease. Neuroimaging Clin N Am 15:837\u2013846 x","journal-title":"Neuroimaging Clin N Am"},{"key":"8019_CR54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3940(95)11270-7","volume":"186","author":"AM Kennedy","year":"1995","unstructured":"Kennedy AM, Frackowiak RS, Newman SK, Bloomfield P, Seaward J, Roques P, Lewington G, Cunningham VJ, Rossor MN (1995) Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer\u2019s disease. Neurosci Lett 186:17\u201320","journal-title":"Neurosci Lett"},{"key":"8019_CR55","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jama.1995.03520360056039","volume":"273","author":"GW Small","year":"1995","unstructured":"Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L et al (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273:942\u2013947","journal-title":"JAMA"},{"key":"8019_CR56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1536-1632(02)00016-1","volume":"4","author":"DH Silverman","year":"2002","unstructured":"Silverman DH, Cummings JL, Small G, Gambhir SS, Chen W, Czernin J, Phelps ME (2002) Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 4:283\u20132893","journal-title":"Mol Imaging Biol"},{"key":"8019_CR57","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","volume":"286","author":"DH Silverman","year":"2001","unstructured":"Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120\u20132127","journal-title":"JAMA"},{"key":"8019_CR58","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00259-003-1194-1","volume":"30","author":"A Drzezga","year":"2003","unstructured":"Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer\u2019s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104\u20131113","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8019_CR59","first-page":"235","volume-title":"Neuronal nicotinic receptors: pharmacology and therapeutic opportunities","author":"VL Villemagne","year":"1998","unstructured":"Villemagne VL, Musachio JL, Scheffel U (1998) Nicotine and related compounds as PET and SPECT ligands. In: Arneric SP, Brioni JD (eds) Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. John Wiley & Sons, New York, pp 235\u2013250"},{"key":"8019_CR60","first-page":"165","volume":"376","author":"A Nordberg","year":"1991","unstructured":"Nordberg A, Hartvig P, Lilja A, Viitanen M, Amberla K, Lundqvist H, Andersson J, Nyback H, Ulin J, Anderson Y et al (1991) Nicotine receptors in the brain of patients with Alzheimer\u2019s disease. Studies with 11C-nicotine and positron emission tomography. Acta Radiol Suppl 376:165\u2013166","journal-title":"Acta Radiol Suppl"},{"key":"8019_CR61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0006-3223(00)01125-2","volume":"49","author":"A Nordberg","year":"2001","unstructured":"Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer\u2019s disease: therapeutic implications. Biol Psychiatry 49:200\u2013210","journal-title":"Biol Psychiatry"},{"key":"8019_CR62","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.2174\/138161206778559605","volume":"12","author":"AG Horti","year":"2006","unstructured":"Horti AG, Villemagne VL (2006) The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharm Des 12:3877\u20133900","journal-title":"Curr Pharm Des"},{"key":"8019_CR63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0166-4328(93)90138-G","volume":"57","author":"A Nordberg","year":"1993","unstructured":"Nordberg A (1993) Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res 57:215\u2013224","journal-title":"Behav Brain Res"},{"key":"8019_CR64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00002093-199809000-00017","volume":"12","author":"A Nordberg","year":"1998","unstructured":"Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellstrom-Lindahl E, Johansson M, Andersson J, Hartvig P, Lilja A, Langstrom B, Winblad B (1998) Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 12:228\u2013237","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"8019_CR65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000106611","volume":"8","author":"A Nordberg","year":"1997","unstructured":"Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahi E, Langstrom B (1997) Imaging of nicotinic and muscarinic receptors in Alzheimer\u2019s disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 8:78\u201384","journal-title":"Dement Geriatr Cogn Disord"},{"key":"8019_CR66","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00213-007-0725-z","volume":"191","author":"A Kadir","year":"2007","unstructured":"Kadir A, Darreh-Shori T, Almkvist O, Wall A, Langstrom B, Nordberg A (2007) Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer\u2019s disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 191:1005\u20131014","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"8019_CR67","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.neurobiolaging.2007.02.020","volume":"29","author":"A Kadir","year":"2007","unstructured":"Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, Ringheim A, Eriksson B, Blomquist G, Langstrom B, Nordberg A (2007) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 29(8):1204\u20131217 doi: 10.1016\/j.neurobiolaging.2007.02.020","journal-title":"Neurobiol Aging"},{"key":"8019_CR68","first-page":"60P","volume":"48","author":"J Ellis","year":"2007","unstructured":"Ellis J, Villemagne VL, Nathan P, Mulligan RS, Gong SJ, O\u2019Keefe G, Tochon-Danguy H, Wesnes K, Savage G, Rowe CC (2007) Galantamine improves cognitive performance without effecting nicotinic receptors in early Alzheimer\u2019s disease as measured by 2[18F]F-A-85380 PET. J Nucl Med 48:60P","journal-title":"J Nucl Med"},{"key":"8019_CR69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","volume":"68","author":"DS Auld","year":"2002","unstructured":"Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer\u2019s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209\u2013245","journal-title":"Prog Neurobiol"},{"key":"8019_CR70","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1385\/JMN:20:3:349","volume":"20","author":"A Fisher","year":"2003","unstructured":"Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R (2003) M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer\u2019s disease: implications in future therapy. J Mol Neurosci 20:349\u2013356","journal-title":"J Mol Neurosci"},{"key":"8019_CR71","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2174\/092986705774454742","volume":"12","author":"HJ Koch","year":"2005","unstructured":"Koch HJ, Haas S, Jurgens T (2005) On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer\u2019s disease. Curr Med Chem 12:2915\u20132921","journal-title":"Curr Med Chem"},{"key":"8019_CR72","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.2174\/138161205774370762","volume":"11","author":"JW Clader","year":"2005","unstructured":"Clader JW, Wang Y (2005) Muscarinic receptor agonists and antagonists in the treatment of Alzheimer\u2019s disease. Curr Pharm Des 11:3353\u20133361","journal-title":"Curr Pharm Des"},{"key":"8019_CR73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14737175.5.2.277","volume":"5","author":"NP Verhoeff","year":"2005","unstructured":"Verhoeff NP (2005) Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer\u2019s disease. Expert Rev Neurother 5:277\u2013284","journal-title":"Expert Rev Neurother"},{"key":"8019_CR74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pneurobio.2006.06.001","volume":"79","author":"S Rossner","year":"2006","unstructured":"Rossner S, Sastre M, Bourne K, Lichtenthaler SF (2006) Transcriptional and translational regulation of BACE1 expression\u2014implications for Alzheimer\u2019s disease. Prog Neurobiol 79:95\u2013111","journal-title":"Prog Neurobiol"},{"key":"8019_CR75","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","volume":"6","author":"J Wess","year":"2007","unstructured":"Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721\u2013733","journal-title":"Nat Rev Drug Discov"},{"key":"8019_CR76","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2174\/138161206778559678","volume":"12","author":"WC Eckelman","year":"2006","unstructured":"Eckelman WC (2006) Imaging of muscarinic receptors in the central nervous system. Curr Pharm Des 12:3901\u20133913","journal-title":"Curr Pharm Des"},{"key":"8019_CR77","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0306-4522(00)00230-X","volume":"99","author":"M Higuchi","year":"2000","unstructured":"Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, Sasaki H (2000) Histamine H(1) receptors in patients with Alzheimer\u2019s disease assessed by positron emission tomography. Neuroscience 99:721\u2013729","journal-title":"Neuroscience"},{"key":"8019_CR78","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","volume":"73","author":"Z Walker","year":"2002","unstructured":"Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL (2002) Differentiation of dementia with Lewy bodies from Alzheimer\u2019s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134\u2013140","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8019_CR79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/WNL.55.2.205","volume":"55","author":"N Kemppainen","year":"2000","unstructured":"Kemppainen N, Ruottinen H, Nagren K, Rinne JO (2000) PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 55:205\u2013209","journal-title":"Neurology"},{"key":"8019_CR80","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","volume":"103","author":"V Kepe","year":"2006","unstructured":"Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME (2006) Serotonin 1A receptors in the living brain of Alzheimer\u2019s disease patients. Proc Natl Acad Sci USA 103:702\u2013707","journal-title":"Proc Natl Acad Sci USA"},{"key":"8019_CR81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","volume":"24","author":"J Versijpt","year":"2003","unstructured":"Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, Goethals I, Audenaert K, Slegers G, Dierckx RA, Korf J (2003) Imaging of the 5-HT2A system: age-, gender-, and Alzheimer\u2019s disease-related findings. Neurobiol Aging 24:553\u2013561","journal-title":"Neurobiol Aging"},{"key":"8019_CR82","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-510X(96)05315-4","volume":"148","author":"RM Cohen","year":"1997","unstructured":"Cohen RM, Andreason PJ, Doudet DJ, Carson RE, Sunderland T (1997) Opiate receptor avidity and cerebral blood flow in Alzheimer\u2019s disease. J Neurol Sci 148:171\u2013180","journal-title":"J Neurol Sci"},{"key":"8019_CR83","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0022-3956(97)00031-9","volume":"31","author":"DR Brown","year":"1997","unstructured":"Brown DR, Wyper DJ, Owens J, Patterson J, Kelly RC, Hunter R, McCulloch J (1997) 123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer\u2019s disease. J Psychiatr Res 31:605\u2013619","journal-title":"J Psychiatr Res"},{"key":"8019_CR84","first-page":"83","volume-title":"The pathophysiology of Alzheimer\u2019s disease","author":"DJ Selkoe","year":"2000","unstructured":"Selkoe DJ (2000) The early diagnosis of Alzheimer\u2019s disease. In: Scinto LFM, Daffner KR (eds) The pathophysiology of Alzheimer\u2019s disease. Humana, Totowa, NJ, USA, pp 83\u2013104"},{"key":"8019_CR85","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.nucmedbio.2007.06.015","volume":"34","author":"CA Mathis","year":"2007","unstructured":"Mathis CA, Lopresti BJ, Klunk WE (2007) Impact of amyloid imaging on drug development in Alzheimer\u2019s disease. Nucl Med Biol 34:809\u2013822","journal-title":"Nucl Med Biol"},{"key":"8019_CR86","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","volume":"25","author":"N Okamura","year":"2005","unstructured":"Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Fujiwara H, Nemoto M, Maruyama M, Arai H, Yanai K, Sawada T, Kudo Y (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer\u2019s disease. J Neurosci 25:10857\u201310862","journal-title":"J Neurosci"},{"key":"8019_CR87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00234-003-1034-9","volume":"46","author":"HI Sair","year":"2004","unstructured":"Sair HI, Doraiswamy PM, Petrella JR (2004) In vivo amyloid imaging in Alzheimer\u2019s disease. Neuroradiology 46:93\u2013104","journal-title":"Neuroradiology"},{"key":"8019_CR88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0969-8051(03)00049-0","volume":"30","author":"M Ono","year":"2003","unstructured":"Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, Kung MP, Kung HF (2003) 11C-labeled stilbene derivatives as abeta-aggregate-specific PET imaging agents for Alzheimer\u2019s disease. Nucl Med Biol 30:565\u2013571","journal-title":"Nucl Med Biol"},{"key":"8019_CR89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/JMN:20:1:15","volume":"20","author":"MP Kung","year":"2003","unstructured":"Kung MP, Skovronsky DM, Hou C, Zhuang ZP, Gur TL, Zhang B, Trojanowski JQ, Lee VM, Kung HF (2003) Detection of amyloid plaques by radioligands for abeta40 and abeta42: potential imaging agents in Alzheimer\u2019s patients. J Mol Neurosci 20:15\u201324","journal-title":"J Mol Neurosci"},{"key":"8019_CR90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0197-4580(00)00237-2","volume":"22","author":"CD Link","year":"2001","unstructured":"Link CD, Johnson CJ, Fonte V, Paupard M, Hall DH, Styren S, Mathis CA, Klunk WE (2001) Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22:217\u2013226","journal-title":"Neurobiol Aging"},{"key":"8019_CR91","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jnen\/61.9.797","volume":"61","author":"WE Klunk","year":"2002","unstructured":"Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT (2002) Imaging Ab plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropath Exp Neurol 61:797\u2013805","journal-title":"J Neuropath Exp Neurol"},{"key":"8019_CR92","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","volume":"23","author":"WE Klunk","year":"2003","unstructured":"Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, DeKosky ST, Mathis CA (2003) The binding of 2-(4\u2032-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086\u20132092","journal-title":"J Neurosci"},{"key":"8019_CR93","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0024-3205(01)01232-2","volume":"69","author":"WE Klunk","year":"2001","unstructured":"Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA (2001) Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69:1471\u20131484","journal-title":"Life Sci"},{"key":"8019_CR94","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0960-894X(01)00734-X","volume":"12","author":"CA Mathis","year":"2002","unstructured":"Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295\u2013298","journal-title":"Bioorg Med Chem Lett"},{"key":"8019_CR95","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.1073\/pnas.2034101100","volume":"100","author":"BJ Bacskai","year":"2003","unstructured":"Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, Mathis CA, Klunk WE, Hyman BT (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 100:12462\u201312467","journal-title":"Proc Natl Acad Sci USA"},{"key":"8019_CR96","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/jlcr.2580440110","volume":"44","author":"CA Mathis","year":"2001","unstructured":"Mathis CA, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE (2001) Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer\u2019s disease. J Labelled Cpd Radiopharm 44:S26\u2013S28","journal-title":"J Labelled Cpd Radiopharm"},{"key":"8019_CR97","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"CA Mathis","year":"2003","unstructured":"Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740\u20132754","journal-title":"J Med Chem"},{"key":"8019_CR98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","volume":"32","author":"W Zhang","year":"2005","unstructured":"Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF (2005) F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting abeta aggregates in the brain. Nucl Med Biol 32:799\u2013809","journal-title":"Nucl Med Biol"},{"key":"8019_CR99","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2004.08.004","volume":"1025","author":"MP Kung","year":"2004","unstructured":"Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF (2004) Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer\u2019s disease. Brain Res 1025:98\u2013105","journal-title":"Brain Res"},{"key":"8019_CR100","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","volume":"355","author":"GW Small","year":"2006","unstructured":"Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652\u20132663","journal-title":"N Engl J Med"},{"key":"8019_CR101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13645700600836000","volume":"15","author":"Y Kudo","year":"2006","unstructured":"Kudo Y (2006) Development of amyloid imaging PET probes for an early diagnosis of Alzheimer\u2019s disease. Minim Invasive Ther Allied Technol 15:209\u2013213","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"8019_CR102","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0306-4522(02)00907-7","volume":"117","author":"ED Agdeppa","year":"2003","unstructured":"Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, Small GW, Cole GM, Barrio JR (2003) In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer\u2019s brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience 117:723\u2013730","journal-title":"Neuroscience"},{"key":"8019_CR103","first-page":"S194","volume":"42","author":"JR Barrio","year":"1999","unstructured":"Barrio JR, Huang SC, Cole G, Satyamurthy N, Petric A, Phelps ME, Small G (1999) PET imaging of tangles and plaques in Alzheimer disease with a highly lipophilic probe. J Labelled Compd Radiopharm 42:S194\u2013S195","journal-title":"J Labelled Compd Radiopharm"},{"key":"8019_CR104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localisation of neurofibrillary tangles and b-amyloid plaques in the brains of living patients with Alzheimer\u2019s disease. Am J Ger Psychiatry 10:24\u201335","journal-title":"Am J Ger Psychiatry"},{"key":"8019_CR105","first-page":"323","volume":"19","author":"GW Small","year":"2002","unstructured":"Small GW, Agdeppa ED, Kepe V, Satyamurthy N, Huang SC, Barrio JR (2002) In vivo brain imaging of tangle burden in humans. J Mol Neurosci 19:323\u2013327","journal-title":"J Mol Neurosci"},{"key":"8019_CR106","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0197-4580(02)00121-5","volume":"23","author":"VM Lee","year":"2002","unstructured":"Lee VM (2002) Related Amyloid binding ligands as Alzheimer\u2019s disease therapies. Neurobiol Aging 23:1039\u20131042","journal-title":"Neurobiol Aging"},{"key":"8019_CR107","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/bc010066z","volume":"13","author":"JR Marshall","year":"2002","unstructured":"Marshall JR, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Maggio JE (2002) Noninvasive imaging of peripherally injected Alzheimer\u2019s disease type synthetic A beta amyloid in vivo. Bioconjug Chem 13:276\u2013284","journal-title":"Bioconjug Chem"},{"key":"8019_CR108","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/bc9901393","volume":"11","author":"A Kurihara","year":"2000","unstructured":"Kurihara A, Pardridge WM (2000) Abeta(1\u201340) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer\u2019s disease brain sections. Bioconjug Chem 11:380\u2013386","journal-title":"Bioconjug Chem"},{"key":"8019_CR109","first-page":"2184","volume":"33","author":"RE Majocha","year":"1992","unstructured":"Majocha RE, Reno JM, Friedland RP, Van Haight C, Lyle LR, Marotta CA (1992) Development of a monoclonal antibody specific for b\/A4 amyloid in Alzheimer\u2019s disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med 33:2184\u20132189","journal-title":"J Nucl Med"},{"key":"8019_CR110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00005072-199407000-00009","volume":"53","author":"LC Walker","year":"1994","unstructured":"Walker LC, Price DL, Voytko ML, Schenk DB (1994) Labelling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol 53:377\u2013383","journal-title":"J Neuropathol Exp Neurol"},{"key":"8019_CR111","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1471-4159.2007.04591.x","volume":"102","author":"JF Poduslo","year":"2007","unstructured":"Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM (2007) In vivo targeting of antibody fragments to the nervous system for Alzheimer\u2019s disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 102:420\u2013433","journal-title":"J Neurochem"},{"key":"8019_CR112","first-page":"1044","volume":"43","author":"J Shi","year":"2002","unstructured":"Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, LaManna JC, Friedland RP (2002) Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 43:1044\u20131051","journal-title":"J Nucl Med"},{"key":"8019_CR113","first-page":"365","volume":"299","author":"YZ Wadghiri","year":"2005","unstructured":"Wadghiri YZ, Sigurdsson EM, Wisniewski T, Turnbull DH (2005) Magnetic resonance imaging of amyloid plaques in transgenic mice. Methods Mol Biol 299:365\u2013379","journal-title":"Methods Mol Biol"},{"key":"8019_CR114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/mrm.20385","volume":"53","author":"G Vanhoutte","year":"2005","unstructured":"Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A (2005) Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer\u2019s disease. Magn Reson Med 53:607\u2013613","journal-title":"Magn Reson Med"},{"key":"8019_CR115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejmech.2004.02.013","volume":"39","author":"K Sato","year":"2004","unstructured":"Sato K, Higuchi M, Iwata N, Saido TC, Sasamoto K (2004) Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem 39:573\u2013578","journal-title":"Eur J Med Chem"},{"key":"8019_CR116","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mrm.10529","volume":"50","author":"YZ Wadghiri","year":"2003","unstructured":"Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH (2003) Detection of Alzheimer\u2019s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50:293\u2013302","journal-title":"Magn Reson Med"},{"key":"8019_CR117","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nn1422","volume":"8","author":"M Higuchi","year":"2005","unstructured":"Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC (2005) (19)F and (1)H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 8:527\u2013533","journal-title":"Nat Neurosci"},{"key":"8019_CR118","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/bi0359574","volume":"43","author":"JF Poduslo","year":"2004","unstructured":"Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, Wengenack TM (2004) Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood\u2013brain barrier permeability, and in vivo targeting to Alzheimer\u2019s disease amyloid plaques. Biochemistry 43:6064\u20136075","journal-title":"Biochemistry"},{"key":"8019_CR119","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1471-4159.2007.04972.x","volume":"104","author":"I Maezawa","year":"2008","unstructured":"Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, Laferla FM, Jin LW (2008) Congo red and thioflavin-T analogs detect abeta oligomers. J Neurochem 104:457\u2013468","journal-title":"J Neurochem"},{"key":"8019_CR120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann Neurol 55:306\u2013319","journal-title":"Ann Neurol"},{"key":"8019_CR121","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1523\/JNEUROSCI.2990-05.2005","volume":"25","author":"WE Klunk","year":"2005","unstructured":"Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer\u2019s disease brain but not in transgenic mouse brain. J Neurosci 25:10598\u201310606","journal-title":"J Neurosci"},{"key":"8019_CR122","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","volume":"23","author":"WE Klunk","year":"2003","unstructured":"Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, DeKosky ST, Mathis CA (2003) The binding of 2-(4\u2032-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086\u20132092","journal-title":"J Neurosci"},{"key":"8019_CR123","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24\u201335","journal-title":"Am J Geriatr Psychiatry"},{"key":"8019_CR124","first-page":"584","volume":"12","author":"NP Verhoeff","year":"2004","unstructured":"Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12:584\u2013595","journal-title":"Am J Geriatr Psychiatry"},{"key":"8019_CR125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2967\/jnumed.106.037556","volume":"48","author":"Y Kudo","year":"2007","unstructured":"Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6-(2-[Fluoro]Ethoxy)Benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer\u2019s disease patients. J Nucl Med 48:553\u2013561","journal-title":"J Nucl Med"},{"key":"8019_CR126","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1474-9726.2006.00196.x","volume":"5","author":"C Opazo","year":"2006","unstructured":"Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI (2006) Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer\u2019s disease. Aging Cell 5:69\u201379","journal-title":"Aging Cell"},{"key":"8019_CR127","first-page":"748","volume":"47","author":"AB Newberg","year":"2006","unstructured":"Newberg AB, Wintering NA, Plossl K, Hochold J, Stabin MG, Watson M, Skovronsky D, Clark CM, Kung MP, Kung HF (2006) Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer\u2019s disease. J Nucl Med 47:748\u2013754","journal-title":"J Nucl Med"},{"key":"8019_CR128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archneur.62.2.196","volume":"62","author":"CA Mathis","year":"2005","unstructured":"Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62:196\u2013200","journal-title":"Arch Neurol"},{"key":"8019_CR129","doi-asserted-by":"crossref","first-page":"23599","DOI":"10.1074\/jbc.M501285200","volume":"280","author":"L Ye","year":"2005","unstructured":"Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A (2005) Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 280:23599\u201323604","journal-title":"J Biol Chem"},{"key":"8019_CR130","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1074\/jbc.M412056200","volume":"280","author":"A Lockhart","year":"2005","unstructured":"Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, Hong G, Gee AD, Brown J (2005) Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer\u2019s disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280:7677\u20137684","journal-title":"J Biol Chem"},{"issue":"Pt 10","key":"8019_CR131","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/brain\/awm191","volume":"130","author":"A Lockhart","year":"2007","unstructured":"Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG (2007) PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis. Brain 130(Pt 10):2607\u20132615","journal-title":"Brain"},{"key":"8019_CR132","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1523\/JNEUROSCI.0673-07.2007","volume":"27","author":"J Maeda","year":"2007","unstructured":"Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer\u2019s disease enabled by positron emission tomography. J Neurosci 27:10957\u201310968","journal-title":"J Neurosci"},{"key":"8019_CR133","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00259-005-1780-5","volume":"32","author":"H Toyama","year":"2005","unstructured":"Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 32:593\u2013600","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8019_CR134","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1006\/bbrc.2000.3490","volume":"276","author":"Y Harigaya","year":"2000","unstructured":"Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG (2000) Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer\u2019s disease brain. Biochem Biophys Res Commun 276:422\u2013427","journal-title":"Biochem Biophys Res Commun"},{"key":"8019_CR135","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1021\/bi0612667","volume":"45","author":"S Schilling","year":"2006","unstructured":"Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45:12393\u201312399","journal-title":"Biochemistry"},{"key":"8019_CR136","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O\u2019Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718\u20131725","journal-title":"Neurology"},{"issue":"11","key":"8019_CR137","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, Dekosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25(11):1528\u20131547","journal-title":"J Cereb Blood Flow Metab"},{"key":"8019_CR138","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1523\/JNEUROSCI.2177-05.2005","volume":"25","author":"RL Buckner","year":"2005","unstructured":"Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer\u2019s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709\u20137717","journal-title":"J Neurosci"},{"key":"8019_CR139","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.21164","volume":"62","author":"KA Johnson","year":"2007","unstructured":"Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62:229\u2013234","journal-title":"Ann Neurol"},{"key":"8019_CR140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archneur.64.3.431","volume":"64","author":"BJ Bacskai","year":"2007","unstructured":"Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 64:431\u2013434","journal-title":"Arch Neurol"},{"key":"8019_CR141","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.20889","volume":"60","author":"HA Archer","year":"2006","unstructured":"Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN (2006) Amyloid load and cerebral atrophy in Alzheimer\u2019s disease: an 11C-PIB positron emission tomography study. Ann Neurol 60:145\u2013147","journal-title":"Ann Neurol"},{"key":"8019_CR142","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, Larossa GN, Spinner ML, Klunk WE, Mathis CA, Dekosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid abeta(42) in humans. Ann Neurol 59:512\u2013519","journal-title":"Ann Neurol"},{"key":"8019_CR143","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/brain\/awm133","volume":"130","author":"N Nelissen","year":"2007","unstructured":"Nelissen N, Vandenbulcke M, Fannes K, Verbruggen A, Peeters R, Dupont P, Van Laere K, Bormans G, Vandenberghe R (2007) Abeta amyloid deposition in the language system and how the brain responds. Brain 130:2055\u20132069","journal-title":"Brain"},{"key":"8019_CR144","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528\u20131547","journal-title":"J Cereb Blood Flow Metab"},{"key":"8019_CR145","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834\u2013840","journal-title":"J Cereb Blood Flow Metab"},{"key":"8019_CR146","first-page":"1959","volume":"46","author":"BJ Lopresti","year":"2005","unstructured":"Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC (2005) Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959\u20131972","journal-title":"J Nucl Med"},{"key":"8019_CR147","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) {beta}-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer\u2019s disease. Brain 130:2837\u20132844","journal-title":"Brain"},{"key":"8019_CR148","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2967\/jnumed.106.037762","volume":"48","author":"S Ng","year":"2007","unstructured":"Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O\u2019Keefe G, Masters CL, Rowe CC (2007) Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer\u2019s disease. J Nucl Med 48:547\u2013552","journal-title":"J Nucl Med"},{"key":"8019_CR149","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0076-6879(99)09020-5","volume":"309","author":"H LeVine 3rd","year":"1999","unstructured":"LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274\u2013284","journal-title":"Methods Enzymol"},{"key":"8019_CR150","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1523\/JNEUROSCI.0630-07.2007","volume":"27","author":"MT Fodero-Tavoletti","year":"2007","unstructured":"Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL (2007) In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27:10365\u201310371","journal-title":"J Neurosci"},{"issue":"4","key":"8019_CR151","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.parkreldis.2007.07.010","volume":"14","author":"A Johansson","year":"2008","unstructured":"Johansson A, Savitcheva I, Forsberg A, Engler H, Langstrom B, Nordberg A, Askmark H (2008) [(11)C]-PIB imaging in patients with Parkinson\u2019s disease: preliminary results. Parkinsonism Relat Disord 14(4):345\u2013347 doi: 10.1016\/j.parkreldis.2007.07.010","journal-title":"Parkinsonism Relat Disord"},{"key":"8019_CR152","first-page":"307","volume":"1","author":"JO Rinne","year":"2007","unstructured":"Rinne JO, Edison P, Rowe CC, Ahmed I, Villemagne VL, Chaudhuri KR, Brooks DJ (2007) Increased amyloid load In Parkinson\u2019s Disease Dementia (PDD) and Lewy Body Dementia (LBD) Measured with 11C-PIB PET. Neurodegenerative Dis 1:307","journal-title":"Neurodegenerative Dis"},{"key":"8019_CR153","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci USA 98:12245\u201312250","journal-title":"Proc Natl Acad Sci USA"},{"key":"8019_CR154","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1212\/01.wnl.0000259035.98480.ed","volume":"68","author":"GD Rabinovici","year":"2007","unstructured":"Rabinovici GD, Furst AJ, O\u2019Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ (2007) 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68:1205\u20131212","journal-title":"Neurology"},{"key":"8019_CR155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00259-007-0523-1","volume":"35","author":"H Engler","year":"2007","unstructured":"Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, Lannfelt L, Langstrom B, Kilander L (2007) In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 35:100\u2013106","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8019_CR156","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.neuroimage.2007.09.020","volume":"39","author":"A Drzezga","year":"2007","unstructured":"Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky ST, Wester HJ, Schwaiger M, Kurz A (2007) Imaging of amyloid-plaques and cerebral glucose metabolism in semantic dementia and Alzheimer\u2019s disease. Neuroimage 39:619\u2013633 doi: 10.1016\/j.neuroimage.2007.09.020. 2007","journal-title":"Neuroimage"},{"key":"8019_CR157","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446\u2013452","journal-title":"Neurology"},{"key":"8019_CR158","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol 45:358\u2013368","journal-title":"Ann Neurol"},{"key":"8019_CR159","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/00005072-199812000-00009","volume":"57","author":"CM Hulette","year":"1998","unstructured":"Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM (1998) Neuropathological and neuropsychological changes in \u201cnormal\u201d aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57:1168\u20131174","journal-title":"J Neuropathol Exp Neurol"},{"key":"8019_CR160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"JC Morris","year":"2001","unstructured":"Morris JC, Price AL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer\u2019s disease. J Mol Neurosci 17:101\u2013118","journal-title":"J Mol Neurosci"},{"key":"8019_CR161","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.410410122","volume":"41","author":"S Whyte","year":"1997","unstructured":"Whyte S, Wilson N, Currie J, Maruff P, Malone V, Shafiq-Antonacci R, Tyler P, Derry KL, Underwood J, Li QX, Beyreuther K, Masters CL (1997) Collection and normal levels of the amyloid precursor protein in plasma. Ann Neurol 41:121\u2013124","journal-title":"Ann Neurol"},{"key":"8019_CR162","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1212\/WNL.56.11.1533","volume":"56","author":"A Collie","year":"2001","unstructured":"Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL, Currie J (2001) Memory decline in healthy older people: implications for identifying mild cognitive impairment. Neurology 56:1533\u20131538","journal-title":"Neurology"},{"key":"8019_CR163","doi-asserted-by":"crossref","unstructured":"Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O\u2019Keefe G, Masters CL, Rowe CC (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer\u2019s disease. Neuropsychologia 46(6):1688\u20131697 doi: 10.1016\/j.neuropsychologia.2008.02.008","DOI":"10.1016\/j.neuropsychologia.2008.02.008"},{"key":"8019_CR164","first-page":"397","volume":"58","author":"JC Morris","year":"2001","unstructured":"Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58:397\u2013405","journal-title":"Arch Neurol"},{"key":"8019_CR165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000095427","volume":"22","author":"K Yaffe","year":"2006","unstructured":"Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B (2006) Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 22:312\u2013319","journal-title":"Dement Geriatr Cogn Disord"},{"key":"8019_CR166","doi-asserted-by":"crossref","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (in press) doi: 10.1016\/j.neurobiolaging.2007.03.029","DOI":"10.1016\/j.neurobiolaging.2007.03.029"},{"key":"8019_CR167","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","volume":"129","author":"H Engler","year":"2006","unstructured":"Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease. Brain 129:2856\u20132866","journal-title":"Brain"},{"key":"8019_CR168","doi-asserted-by":"crossref","first-page":"T100","DOI":"10.1016\/j.neuroimage.2006.04.087","volume":"21","author":"N Tolboom","year":"2006","unstructured":"Tolboom N, Yaqub M, Lubberink M, Kloet RW, Boellaard R, Windhorst B, Scheltens P, Lammertsma A, van Berckel BN (2006) Test\u2013retest variability of [11C]PIB studies in healthy subjects and AD patients. Neuroimage 21:T100","journal-title":"Neuroimage"},{"key":"8019_CR169","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","volume":"43","author":"AM Saunders","year":"1993","unstructured":"Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ et al (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer\u2019s disease. Neurology 43:1467\u20131472","journal-title":"Neurology"},{"key":"8019_CR170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0361-9230(03)00067-4","volume":"61","author":"A Rocchi","year":"2003","unstructured":"Rocchi A, Pellegrini S, Siciliano G, Murri L (2003) Causative and susceptibility genes for Alzheimer\u2019s disease: a review. Brain Res Bull 61:1\u201324","journal-title":"Brain Res Bull"},{"key":"8019_CR171","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","volume":"27","author":"WE Klunk","year":"2007","unstructured":"Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174\u20136184","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"8019_CR172","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S1041610297004973","volume":"9","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E (1997) Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 9(Suppl 1):257\u2013261 (discussion 269\u2013272)","journal-title":"Int Psychogeriatr"},{"key":"8019_CR173","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791\u20131800","journal-title":"Neurology"},{"key":"8019_CR174","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/WNL.38.11.1688","volume":"38","author":"L Davies","year":"1988","unstructured":"Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer\u2019s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38:1688\u20131693","journal-title":"Neurology"},{"key":"8019_CR175","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archneur.64.8.1140","volume":"64","author":"SY Ng","year":"2007","unstructured":"Ng SY, Villemagne VL, Masters CL, Rowe CC (2007) Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh compound B. Arch Neurol 64:1140\u20131144","journal-title":"Arch Neurol"},{"key":"8019_CR176","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1385\/JMN:24:1:049","volume":"24","author":"MP Kung","year":"2004","unstructured":"Kung MP, Zhuang ZP, Hou C, Kung HF (2004) Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. J Mol Neurosci 24:49\u201353","journal-title":"J Mol Neurosci"},{"key":"8019_CR177","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nucmedbio.2004.10.002","volume":"32","author":"ZP Zhuang","year":"2005","unstructured":"Zhuang ZP, Kung MP, Hou C, Ploessl K, Kung HF (2005) Biphenyls labeled with technetium 99m for imaging beta-amyloid plaques in the brain. Nucl Med Biol 32:171\u2013184","journal-title":"Nucl Med Biol"},{"key":"8019_CR178","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL (2008) Imaging of amyloid beta in Alzheimer\u2019s disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129\u2013135","journal-title":"Lancet Neurol"},{"key":"8019_CR179","first-page":"56P","volume":"48","author":"CA Mathis","year":"2007","unstructured":"Mathis CA, Lopresti BJ, Mason N, Price J, Flatt N, Bi W, Ziolko S, DeKosky S, Klunk WE (2007) Comparison of the amyloid imaging agents [F-18]3\u2032-F-PIB and [C-11]PIB in Alzheimer\u2019s disease and control subjects. J Nucl Med 48:56P","journal-title":"J Nucl Med"},{"issue":"Suppl 4","key":"8019_CR180","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/00002093-200307004-00004","volume":"17","author":"S DeKosky","year":"2003","unstructured":"DeKosky S (2003) Early intervention is key to successful management of Alzheimer disease. Alzheimer Dis Assoc Disord 17(Suppl 4):S99\u2013S104","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"8019_CR181","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1196\/annals.1379.012","volume":"1097","author":"MJ Leon de","year":"2007","unstructured":"de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H (2007) Imaging and CSF studies in the preclinical diagnosis of Alzheimer\u2019s disease. Ann N Y Acad Sci 1097:114\u2013145","journal-title":"Ann N Y Acad Sci"},{"key":"8019_CR182","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0197-4580(03)00002-2","volume":"24","author":"RA Frank","year":"2003","unstructured":"Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ (2003) Biological markers for therapeutic trials in Alzheimer\u2019s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer\u2019s disease. Neurobiol Aging 24:521\u2013536","journal-title":"Neurobiol Aging"},{"key":"8019_CR183","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-Ab antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 98:8850\u20138855","journal-title":"Proc Natl Acad Sci USA"},{"key":"8019_CR184","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"CW Ritchie","year":"2003","unstructured":"Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685\u20131691","journal-title":"Arch Neurol"},{"key":"8019_CR185","first-page":"55","volume":"4","author":"W Xia","year":"2003","unstructured":"Xia W (2003) Amyloid inhibitors and Alzheimer\u2019s disease. Curr Opin Investig Drugs 4:55\u201359","journal-title":"Curr Opin Investig Drugs"},{"key":"8019_CR186","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.coi.2004.07.012","volume":"16","author":"D Schenk","year":"2004","unstructured":"Schenk D, Hagen M, Seubert P (2004) Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16:599\u2013606","journal-title":"Curr Opin Immunol"},{"key":"8019_CR187","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O\u2019Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734\u2013746","journal-title":"Lancet Neurol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-008-8019-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-008-8019-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-008-8019-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:05:52Z","timestamp":1709179552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-008-8019-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":187,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["8019"],"URL":"https:\/\/doi.org\/10.1007\/s12035-008-8019-y","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}